## Founding Date | 2008 |

## Total Funding | $248.7 m |

## Investors | New Leaf Venture Partners, Delphi Ventures, Foresite Capital |

Karyopharm Therapeutics is a subsidiary of Biogen

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|

## Revenue | 387.0k | 229.0k | 250.0k | 154.0k | 30.3m | 40.9m | 108.1m | |

| (41%) | 9% | ||||||

## R&D expense | 28.5m | 60.1m | 97.7m | 86.9m | 107.3m | 161.4m | 122.3m | 150.8m |

## General and administrative expense | 5.9m | 15.9m | 21.6m | 23.9m | 24.9m | 48.8m | 105.4m | 126.4m |

## Operating expense total | 34.3m | 76.1m | 119.3m | 110.9m | 132.1m | 210.2m | 227.8m | 277.2m |

## EBIT | (33.9m) | (75.8m) | (119.1m) | (110.7m) | (130.5m) | (179.9m) | (189.3m) | (171.8m) |

| (8773%) | (33121%) | (47630%) | (71904%) | (593%) | (463%) | (159%) | |

## Interest expense | 895.0k | 1.3m | 1.6m | 1.5m | 10.3m | |||

## Interest income | 3.0k | 97.0k | 897.0k | 1.3m | 1.7m | 4.0m | 5.4m | 2.8m |

## Pre tax profit | (109.4m) | (128.9m) | (178.4m) | (199.5m) | (196.0m) | |||

## Income tax expense | (33.9m) | (76.3m) | (118.1m) | 139.0k | 63.0k | 26.0k | 40.0k | 309.0k |

## Net Income | (33.9m) | (75.8m) | (118.2m) | (109.6m) | (129.0m) | (178.4m) | (199.6m) | (196.3m) |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|

## Cash | 156.0m | 150.6m | 58.4m | 49.7m | 69.0m | 118.0m | 128.9m | 85.9m |

## Accounts Receivable | 7.9m | |||||||

## Prepaid Expenses | 2.0m | 2.0m | 2.0m | 1.8m | 6.4m | 7.3m | 9.3m | |

## Inventories | 2.1m | 346.0k | 2.6m | |||||

## Current Assets | 158.0m | 207.8m | 177.6m | 131.6m | 148.4m | 334.6m | 278.6m | 276.5m |

## PP&E | 240.0k | 2.8m | 3.5m | 2.8m | 2.2m | 3.9m | 3.0m | 2.2m |

## Total Assets | 158.2m | 220.3m | 215.4m | 180.4m | 180.3m | 341.2m | 295.0m | 313.1m |

## Accounts Payable | 1.7m | 6.3m | 3.8m | 4.8m | 5.7m | 4.3m | 985.0k | 4.5m |

## Short-term debt | 1.9m | |||||||

## Current Liabilities | 3.3m | 12.3m | 15.1m | 16.5m | 49.5m | 46.9m | 46.4m | 60.2m |

## Long-term debt | 13.2m | 142.4m | ||||||

## Total Debt | 13.2m | 144.3m | ||||||

## Total Liabilities | 13.5m | 17.1m | 18.1m | 50.8m | 158.0m | 245.2m | 262.5m | |

## Common Stock | 3.0k | 3.0k | 4.0k | 5.0k | 6.0k | 7.0k | 7.0k | |

## Additional Paid-in Capital | 217.5m | 345.2m | 455.2m | 528.6m | 625.0m | 857.2m | 923.1m | 1.1b |

## Retained Earnings | (138.3m) | (256.5m) | (366.1m) | (495.3m) | (673.7m) | (873.3m) | (1.1b) | |

## Total Equity | 154.9m | 206.8m | 198.4m | 162.2m | 129.5m | 183.2m | 49.8m | 50.5m |

## Financial Leverage | 1 x | 1.1 x | 1.1 x | 1.1 x | 1.4 x | 1.9 x | 5.9 x | 6.2 x |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|

## Net Income | (33.9m) | (75.8m) | (118.2m) | (109.6m) | (129.0m) | (178.4m) | (199.6m) | (196.3m) |

## Depreciation and Amortization | 144.0k | 323.0k | 634.0k | 717.0k | 713.0k | 735.0k | 974.0k | 972.0k |

## Accounts Receivable | (7.9m) | (5.0m) | ||||||

## Inventories | (346.0k) | (2.6m) | ||||||

## Accounts Payable | 664.0k | 4.5m | (2.4m) | 945.0k | 909.0k | (1.4m) | (3.3m) | 3.5m |

## Cash From Operating Activities | (30.3m) | (51.4m) | (94.0m) | (84.4m) | (73.7m) | (159.1m) | (190.8m) | (160.2m) |

## Purchases of PP&E | (57.0k) | (2.8m) | (1.4m) | (70.0k) | (62.0k) | (2.4m) | (206.0k) | (145.0k) |

## Cash From Investing Activities | (57.0k) | (67.0m) | (90.8m) | 24.6m | 17.1m | (107.7m) | 78.5m | (53.7m) |

## Cash From Financing Activities | 185.9m | 113.1m | 92.7m | 51.2m | 75.7m | 316.1m | 124.3m | 172.1m |

## Net Change in Cash | 155.6m | (5.4m) | (92.3m) | (8.7m) | 19.3m | 49.3m | 12.0m | (41.6m) |

- Source: SEC Filings

- Source: SEC Filings

USD | Q3, 2013 |
---|---|

## Financial Leverage | -1.2 x |